Investor Deadline Looming
If you suffered losses in Allarity Therapeutics, Inc. between May 17, 2022, and July 19, 2024, take note – the deadline to file a lead plaintiff motion is approaching fast, set for November 12, 2024. Glancy Prongay & Murray LLP, the law firm representing investors, sent out a reminder about this pivotal date.
History of Stock Plummets
Allarity Therapeutics’ stock has weathered a series of setbacks. In February 6, 2023, the company divulged about an SEC document production request regarding its NDA for Dovitinib or Dovitinib-DRP, causing a 3.8% stock price drop. Later, on December 11, 2023, the CEO’s termination led to a significant 13.4% decrease in stock value. Finally, adverse news on July 22, 2024, regarding a Wells Notice from the SEC resulted in a further 2.4% decline in the share price.
Allegations of Misconduct
The class action lawsuit accuses Allarity Therapeutics of making false statements and concealing material information during the Class Period. The complaint alleges that the company and its former officers engaged in illegal activities relating to the Dovitinib NDA and Dovitinib-DRP PMA, which increased the risk of regulatory scrutiny and legal repercussions. The failure to disclose this misconduct misled investors about the business’s actual state and prospects.
Legal Action and Rights
Investors with losses stemming from Allarity Therapeutics’ stock performance during the Class Period have until November 12, 2024, to seek appointment as a lead plaintiff in the lawsuit. Even if you do not take immediate action, you are automatically part of the class action and can choose to engage legal counsel or remain a passive member. For more details or questions regarding this case, contact Glancy Prongay & Murray LLP directly.
Stay Updated
For ongoing updates, follow Glancy Prongay & Murray LLP on social media platforms like LinkedIn, Twitter, and Facebook. Stay informed about developments in the case and protect your investment interests.
Contact Information
If you wish to learn more about the pending class action lawsuit, contact Charles Linehan, Esquire, of GPM at 1925 Century Park East, Suite 2100, Los Angeles, California 90067. Reach out via phone at 310-201-9150 or Toll-Free at 888-773-9224, or email at shareholders@glancylaw.com. Visit their official website for further details.
This article is for informational purposes only and should not be considered as investment advice.